Filing Flows › Arcadia Biosciences (RKDA) › Who owns the stock
Who owns Arcadia Biosciences (RKDA) stock
15 funds reported Arcadia Biosciences (RKDA) shares in their latest 13F filings, worth $102K in all. The largest holder is Vanguard Group ($28K). Last quarter 6 funds added to their stakes and 9 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Vanguard Group | 14,038 | $28K | unchanged | 2025-12-31 |
| Citadel Advisors LLC | 23,738 | $16K | new | 2026-06-30 |
| Virtu Financial LLC | 21,786 | $15K | new | 2026-06-30 |
| Geode Capital Management, LLC | 16,135 | $11K | decrease | 2026-06-30 |
| XTX Topco | 15,475 | $11K | new | 2026-06-30 |
| State Street | 12,146 | $8K | unchanged | 2026-06-30 |
| Jane Street Group, LLC | 10,245 | $7K | new | 2026-06-30 |
| Vanguard Capital Management LLC | 9,644 | $7K | unchanged | 2026-06-30 |
| SBI Securities | 120 | $81 | unchanged | 2026-06-30 |
| UBS Group AG | 35 | $24 | decrease | 2026-06-30 |
| TD Waterhouse Canada | 70 | $19 | unchanged | 2026-09-30 |
| Group One Trading LLC | 18 | $12 | unchanged | 2026-06-30 |
| Southern Michigan Bank & Trust | 2 | $1 | unchanged | 2026-09-30 |
| Morgan Stanley | 2 | $1 | unchanged | 2026-06-30 |
| Barclays | 1 | $0 | new | 2026-09-30 |
Arcadia Biosciences' latest quarter
Arcadia Biosciences, Q2 2026: revenue $1.4M (-0.8% year over year), operating margin -34.4%, net loss $6.3M, operating cash flow −$319K. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most RKDA stock?
By the latest 13F filings: Vanguard Group ($28K); Citadel Advisors LLC ($16K); Virtu Financial LLC ($15K); Geode Capital Management, LLC ($11K); XTX Topco ($11K).
What is the short interest in RKDA?
342,847 shares were sold short at the 2026-10-15 settlement, 286.3% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.